

**Amendments to the Specification:**

NOTICE: THIS APPLICATION IS A REISSUE APPLICATION, AND (i) *Amendments in reissue applications do not fall under 37 CFR § 1.121: “Any amendment to the description and claims in reissue applications must be made in accordance with § 1.173.” 37 CFR § 1.121(i).* **Accordingly, do not send a notice alleging that this paper fails to comply with 37 CFR § 1.121.**

**AMEND THE PARAGRAPH AT COLUMN 10, LINES 43-50 AS FOLLOWS:**

As compounds having calcium antagonistic activity, while mention is made of diltiazem hydrochloride, [terodiline] **terolidine** hydrochloride, nicardipine hydrochloride, [valnidipine] **barnidipine** hydrochloride, [flunariziim] **flunarizine** hydrochloride, [varapamyl] **verapamil** hydrochloride, manidipine hydrochloride, cinnarizine, nisoldipine, nitrendipine, nifedipine, nilvadipine, felodipine, nildipine, nimodipine, penidipine and-benidipine; mention is also made of a mixture of them or a combination of them.